Hormone Refractory Prostate Cancer (HRPCA) Market Revenue Continues to Dominate with CAGR of 8.9% Globally to 2027 : AbbVie Inc., Acceleron Pharma Inc., Etc.
The Hormone Refractory Prostate Cancer (HRPCA) market is projected to grow at a rate of 8.9% in terms of value, from USD 8.56 Billion in 2019 to reach USD 17.05 Billion by 2027.
View full press release